Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Galapagos NV - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
GLPG
Nasdaq
2834
www.glpg.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Galapagos NV
Galapagos Third Quarter 2024 Earnings: €0.74 loss per share (vs €0.39 profit in 3Q 2023)
- Nov 2nd, 2024 7:42 am
Galapagos NV (GLPG) Q3 2024 Earnings Call Highlights: Strong Cash Position and R&D Progress ...
- Nov 1st, 2024 7:03 am
Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update
- Oct 30th, 2024 8:01 pm
Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth
- Oct 7th, 2024 5:00 am
Galapagos receives transparency notification from EcoR1 Capital
- Sep 30th, 2024 8:01 pm
Galapagos receives transparency notification from FMR LLC
- Sep 3rd, 2024 8:01 pm
Even after rising 13% this past week, Galapagos (AMS:GLPG) shareholders are still down 82% over the past five years
- Sep 1st, 2024 7:57 am
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
- Aug 28th, 2024 2:11 pm
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study
- Aug 23rd, 2024 11:43 am
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma
- Aug 23rd, 2024 5:00 am
ADAP: 2Q24 Earnings Review: Tecelra FDA Approval + Capital Reload
- Aug 12th, 2024 12:47 pm
BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology
- Aug 1st, 2024 8:01 pm
Galapagos reports half-year 2024 financial results and provides second quarter business update
- Aug 1st, 2024 8:01 pm
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024
- Jun 14th, 2024 8:01 pm
Retail investors are Galapagos NV's (AMS:GLPG) biggest owners and were hit after market cap dropped €74m
- Jun 14th, 2024 4:23 am
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
- May 30th, 2024 8:01 pm
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
- May 30th, 2024 8:01 pm
Galapagos creates new subscription right plans
- May 16th, 2024 8:01 pm
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.
- May 15th, 2024 8:01 pm
Galapagos NV (NASDAQ:GLPG) Q1 2024 Earnings Call Transcript
- May 6th, 2024 2:47 pm
Scroll